GAUDIUMIVF Gaudium IVF and Women Health Q4 FY26 results (Jan–Mar 2026) and concall
Gaudium IVF reported strong financial performance for Q4 and FY26, with significant YoY growth in revenue, EBITDA, and PAT. The company successfully completed its IPO, raising approximately INR 165 crore, and is now debt-light, positioning it for aggressive expansion. Strategic initiatives include integrating AI-led embryology for improved success rates and expanding its hub-and-spoke model, alongside efforts to enhance affordability and manage trade receivables.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 12.7%, net profit up 29.4% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 14 | 27 | 18 | 32 | 25 +70% | 30 +13% |
| EBITDA | 6 | 9 | 5 | 14 | 7 +16% | 12 +40% |
| Net profit | 3 | 6 | 3 | 9 | 4 +7% | 8 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
